



Protected when completed

This is a draft version only. Do not submit to any funding organization. Only the final version from the History page can be submitted. It is strictly forbidden to submit this draft version to an organization that is not a member of the CCV. The complete list of CCV members is available at www.ccv-cvc.ca

Personal Information

Identification

Dr. Jean-Louis Chiasson

Correspondence language: English

Sex: Male

Date of Birth: 8/25

Canadian Residency Status: Canadian Citizen

Country of Citizenship: Canada

Language Skills

Language	Read	Write	Speak	Understand
English	Yes	Yes	Yes	Yes
French	Yes	Yes	Yes	Yes

Address

The primary address is denoted by (*)

Courier	Primary Affiliation (*)
CRCHUM Hôtel-Dieu 3850 St. Urbain Street Masson Pavillon, Rm 8-202 Montréal H2W 1T7 Canada, Quebec	CRCHUM Hôtel-Dieu 3850 St. Urbain Street Masson Pavillon, Rm 8-202 Montréal H2W 1T7 Canada, Quebec

Telephone

The primary telephone is denoted by (*)

Fax	514-4127208
Work	514-8908000 extension: 12923
Work (*)	514-8908000 extension: 12732

Email

The primary email is denoted by (*)

Work (*)	jean.louis.chiasson@umontreal.ca
----------	----------------------------------

User Profile

Disciplines Trained In: Endocrinology

Research Disciplines: Endocrinology

Areas of Research: Diabetes, Hormonal Regulation, Metabolism, Nutrition, Pharmacoepidemiology

Fields of Application: Biomedical Aspects of Human Health, Pathogenesis and Treatment of Diseases

Research Specialization Keywords: carbohydrate metabolism, complications, diabetes mellitus, glucagon secretion/action, glucose turnover, insulin secretion/action, isotopic technique, nutrition/treatment, organ perfusion, prevention

Education

Degrees

1970/7 - 1975/7	Diploma - Certification - Endocrinology - McGill University - Completed
1967/7 - 1968/7	Doctorate - LMCC - M.D. - Endocrinologist - Medical Research Council of Canada - Completed
1963/9 - 1967/7	Doctorate - M.D. - Medical Doctor - Université Laval - Completed
1961/9 - 1963/7	Bachelor's - B.A. - Chemistry - Sainte-Anne - Completed

Employment

Academic Work Experience

1992/10 -	Chief, Research Group on Diabetes and Metabolic Regulation CRCHUM
1992/7 -	Full Professor Université de Montréal - Médecine
1980/7 -	Endocrinologist CHUM

Affiliations

The primary affiliation is denoted by (*)

(*) 1992/7 -	Full Professor - Médecine - Université de Montréal
--------------	--

Research Funding History

Awarded

2012/5 - 2019/5 Principal Investigator	The effect of dulaglutide on major cardiovascular events in patients with type 2 diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND). Principal Investigator : Jean-Louis Chiasson
---	---

	<p>Funding Sources</p> <table border="1"> <tr> <td>2012/5 - 2019/5</td> <td>Clinical randomized trial Eli Lilly Canada Inc. Total Funding: 266220 (Canadian dollar) Funding Competitive?: No</td> </tr> </table>	2012/5 - 2019/5	Clinical randomized trial Eli Lilly Canada Inc. Total Funding: 266220 (Canadian dollar) Funding Competitive?: No
2012/5 - 2019/5	Clinical randomized trial Eli Lilly Canada Inc. Total Funding: 266220 (Canadian dollar) Funding Competitive?: No		
2012/6 - 2017/6 Co-applicant	<p>Determinants of increased risk of cardio-vascular diseases in HIV-infected individuals.</p> <p>Funding Sources</p> <table border="1"> <tr> <td>2012/6 - 2017/6</td> <td>Subvention d'équipe: VIH/sida et comorbidités Canadian Institutes of Health Research (CIHR) Total Funding: 497945 (Canadian dollar) Funding Competitive?: Yes</td> </tr> </table>	2012/6 - 2017/6	Subvention d'équipe: VIH/sida et comorbidités Canadian Institutes of Health Research (CIHR) Total Funding: 497945 (Canadian dollar) Funding Competitive?: Yes
2012/6 - 2017/6	Subvention d'équipe: VIH/sida et comorbidités Canadian Institutes of Health Research (CIHR) Total Funding: 497945 (Canadian dollar) Funding Competitive?: Yes		
2011/4 - 2016/4 Principal Investigator	<p>Étude de phase IV multicentrique, à répartition aléatoire et à double insu avec contrôle par placebo visant à évaluer l'effet de la saxagliptine sur l'incidence du décès d'origine cardiovasculaire, de l'infarctus du myocarde ou de l'AVC ischémique..</p> <p>Co-investigateur : Sophie Bernard</p> <p>Funding Sources</p> <table border="1"> <tr> <td>2011/4 - 2016/4</td> <td>AstraZeneca Canada Inc. Total Funding: 187500 (Canadian dollar) Funding Competitive?: No</td> </tr> </table>	2011/4 - 2016/4	AstraZeneca Canada Inc. Total Funding: 187500 (Canadian dollar) Funding Competitive?: No
2011/4 - 2016/4	AstraZeneca Canada Inc. Total Funding: 187500 (Canadian dollar) Funding Competitive?: No		
2010/1 - 2015/1 Principal Investigator	<p>TECOS: A randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with sitagliptin in patients with type 2 diabetes mellitus and inadequate glycemic control on mono- or dual combination on oral...</p> <p>Principal Investigator : Chiasson, Jean-Louis; Étude multicentrique;</p> <p>Funding Sources</p> <table border="1"> <tr> <td>2009/11 - 2015/11</td> <td>Clinical trial Merck & Co. Inc Total Funding: 320000 (Canadian dollar) Funding Competitive?: No</td> </tr> </table>	2009/11 - 2015/11	Clinical trial Merck & Co. Inc Total Funding: 320000 (Canadian dollar) Funding Competitive?: No
2009/11 - 2015/11	Clinical trial Merck & Co. Inc Total Funding: 320000 (Canadian dollar) Funding Competitive?: No		
2012/5 - 2014/5 Principal Investigator	<p>The impact of LY2605541 versus insulin glargine for patients with type 1 diabetes mellitus treated with preprandial insulin lispro: a double-blind, randomized, 52-week study. The IMAGINE 3 Study.</p> <p>Co-investigateur : Sophie Bernard</p> <p>Funding Sources</p> <table border="1"> <tr> <td>2012/5 - 2014/5</td> <td>Clinical randomized trial Eli Lilly Canada Inc. Total Funding: 141552 (Canadian dollar) Funding Competitive?: No</td> </tr> </table>	2012/5 - 2014/5	Clinical randomized trial Eli Lilly Canada Inc. Total Funding: 141552 (Canadian dollar) Funding Competitive?: No
2012/5 - 2014/5	Clinical randomized trial Eli Lilly Canada Inc. Total Funding: 141552 (Canadian dollar) Funding Competitive?: No		
2011/7 - 2013/7 Principal Investigator	<p>A 24-week, multicenter, international, randomized (1:1), parallel-group, open-label, comparative study of insulin glargine versus liraglutide in insulin-naive patients with type 2 diabetes treated with oral agents and not adequately controlled with...</p> <p>Co-investigateur : Sophie Bernard</p>		

	<p>Funding Sources</p> <p>2011/7 - 2013/7 Sanofi-aventis Total Funding: 53450 (Canadian dollar) Funding Competitive?: No</p>
2012/7 - 2013/6 Principal Applicant	<p>Quelle est l'évidence justifiant la recommandation d'utiliser 1 mg de glucagon pour corriger l'hyperglycémie sévère chez le sujet avec diabète de type 1 ?</p> <p>Principal Applicant : Jean-Louis Chiasson</p> <p>Funding Sources</p> <p>2012/7 - 2013/6 Diabetes Québec Total Funding: 20000 (Canadian dollar) Funding Competitive?: Yes</p>
2012/5 - 2013/5 Principal Investigator	<p>6-month, multicenter, randomized, open-label, parallel-group study comparing the efficacy and safety of a new formulation of insulin glargine and Lantus both plus mealtime insulin in patients with type 2 diabetes mellitus with a 6-mo safety extension</p> <p>Co-investigator : Sophie Bernard</p> <p>Funding Sources</p> <p>2012/5 - 2013/5 Clinical randomized trial Sanofi-aventis Total Funding: 58536 (Canadian dollar) Funding Competitive?: No</p>
2010/3 - 2013/3 Co-applicant	<p>Autogestion du diabète et dépression</p> <p>Principal Investigator : Marie-Dominique Beaulieu</p> <p>Funding Sources</p> <p>2010/3 - 2013/3 Operating grant Canadian Institutes of Health Research (CIHR) Total Funding: 232883 (Canadian dollar) Funding Competitive?: Yes</p>
2011/2 - 2013/2 Principal Investigator	<p>A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of canagliflozin compared with placebo in the treatment of older subjects with type 2 diabetes mellitus inadequately..</p> <p>Co-investigator : Sophie Bernard</p> <p>Funding Sources</p> <p>2011/2 - 2013/2 Clinical trial, Janssen Inc. Janssen-Ortho Inc. Total Funding: 94918 (Canadian dollar) Funding Competitive?: No</p>
2011/4 - 2012/4 Principal Investigator	<p>A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 mg and 25 mg once daily) and sitagliptin (100 mg once daily) given for a minimum of 76 weeks (incl. 24 weeks of preceding trial)...</p> <p>Co-investigator : Sophie Bernard</p>

	Funding Sources	
	2011/4 - 2012/6	Clinical trial, Boehringer Ingelheim Boehringer Ingelheim Total Funding: 52814 (Canadian dollar) Funding Competitive?: No
2010/1 - 2011/1 Co-applicant	VIH et prévention des comorbidités: Adapter et valider une intervention virtuelle visant à réduire les facteurs de risque liés aux maladies cardiovasculaires et au diabète chez les personnes vivant avec le VIH. Principal Investigator : Josée Coté	
	Funding Sources	
	2010/1 - 2011/1	Operating grant Canadian Institutes of Health Research (CIHR) Total Funding: 99956 (Canadian dollar) Funding Competitive?: Yes

Completed

2011/1 - 2012/1 Co-applicant	A randomized trial evaluating the effect of liraglutide versus insulin glargine on hepatic steatosis as measured by MRI and MRS in metformin-treated patients with type 2 diabetes. Principal Investigator : An Tang	
	Funding Sources	
	2010/1 - 2011/1	RSNA R&E Foundation Fonds de la Recherche en Santé du Québec (FRSQ) Total Funding: 47500 (Canadian dollar) Funding Competitive?: Yes
2007/7 - 2011/7 Co-applicant	Rigorous evaluation and integration medicine in aboriginal diabetes care. Principal Investigator : Pierre Haddad	
	Funding Sources	
	2007/7 - 2011/7	Team in Traditional Aboriginal Plants Against Diabetes Canadian Institutes of Health Research (CIHR) Total Funding: 850000 (Canadian dollar) Funding Competitive?: Yes
2010/9 - 2011/3 Principal Investigator	A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 24 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control. Co-investigator : Sophie Bernard	
	Funding Sources	
	2010/9 - 2011/3	Clinical trial, Boehringer Ingelheim Boehringer Ingelheim Total Funding: 52814 (Canadian dollar) Funding Competitive?: No
2010/1 - 2011/1 Co-applicant	Essai randomisé du liraglutide versus l'insuline glargine sur la stéatose hépatique... Principal Investigator : An Tang	

	<p>Funding Sources</p> <p>2010/1 - 2011/1 Diabetes Québec Total Funding: 20000 (Canadian dollar) Funding Competitive?: Yes</p>
2010/1 - 2011/1 Co-applicant	<p>Essai randomisé du liraglutide versus l'insuline glargine sur la stéatose hépatique mesurée par résonance magnétique chez les patients atteints de diabète de type 2 traités à la metformine.</p> <p>Principal Investigator : Tang, An; Dr Jean-Louis Chiasson</p> <p>Funding Sources</p> <p>2010/1 - 2011/1 Canadian Heads of Academic Radiology (CHAR) Total Funding: 7500 (Canadian dollar) Funding Competitive?: Yes</p>
2007/7 - 2010/7 Co-applicant	<p>Estimating the prevalence of diabetes using multiple tests: A validation of the national diabetes surveillance system definition.</p> <p>Principal Investigator : Elham Rahme</p> <p>Funding Sources</p> <p>2007/7 - 2010/7 INMD Diabetes Surveillance Systems/CIHR Canadian Institutes of Health Research (CIHR) Total Funding: 299999 (Canadian dollar) Funding Competitive?: Yes</p>
2009/1 - 2010/1 Co-applicant	<p>Innovation in cardiovascular imaging and image-guided therapy to improve patient management.</p> <p>Principal Investigator : Gilles Soulez</p> <p>Funding Sources</p> <p>2009/1 - 2010/1 FCI 20974 Canada Foundation for Innovation (CFI) Total Funding: 1199774 (Canadian dollar) Funding Competitive?: Yes</p>
2007/7 - 2009/7 Co-applicant	<p>The DREAM On Study (an observational study). Diabetes REduction Assessment with ramipril and rosiglitazone Medication Ongoing evaluation.</p> <p>Principal Investigator : Hertz C. Gerstein</p> <p>Funding Sources</p> <p>2007/7 - 2008/7 Clinical Trial Canadian Institutes of Health Research (CIHR) Total Funding: 13500 (Canadian dollar) Funding Competitive?: No</p>
2007/6 - 2008/12 Principal Investigator	<p>A multicenter, randomized, double-blind study to evaluate the safety and efficacy of the addition of sitagliptin (MK-0431) to patients with type 2 diabetes mellitus who have inadequate glycemic control on insulin therapy (alone or in combination...)</p> <p>Co-investigator : Rémi Rabasa-Lhoret</p> <p>Funding Sources</p> <p>2007/6 - 2008/12 Merck Frosst Canada Inc Total Funding: 52312 (Canadian dollar) Funding Competitive?: No</p>

2007/11 - 2008/11 Principal Investigator	A 12-week, randomized, multicenter, double-blind, placebo-controlled study, assessing the safety and efficacy of ID1101 in obese patients	
	Co-investigator : Rémi Rabasa-Lhoret	
Funding Sources		
2007/11 - 2008/11	Innodia Inc.	Total Funding: 62520 (Canadian dollar)
		Funding Competitive?: No

Activities

Supervisory Activities

Student/Postdoctoral Supervision

Co-Supervisor	Sima Aurelia - Doctorate - Université de Montréal - In Progress Student Degree Start Date: 2009/1 Student Degree Expected Date: 2013/6 Project Description: L'acide rétinolique dans l'obésité et le diabète de type 2 Present Position: Ph.D. Student
Principal Supervisor	Lorena Iglesias - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2009/1 Student Degree Received Date: 2011/6 Project Description: Évaluation d'un prototype d'un détecteur de glucose photonique. Present Position: public sector
Co-Supervisor	Constantin Manolescu Daniel - Doctorate - Université de Montréal - In Progress Student Degree Start Date: 2009/1 Student Degree Expected Date: 2013/6 Project Description: Retinoic acid and insulin resistance in the development of type 2 diabetes Present Position: Ph.D. Student
Co-Supervisor	Janie Houle, - Post-doctorate - UQAM - Completed Student Degree Start Date: 2007/1 Student Degree Received Date: 2011/12 Project Description: Impact de la dépression sur les comportements d'auto-gestion du diabète Present Position: academic sector
Principal Supervisor	Zebdi Samia - Bachelor's - UQTR - Completed Student Degree Start Date: 2007/1 Student Degree Received Date: 2007/4 Project Description: Le rôle de l'hyperglycémie post-prandiale dans les complications coronariennes
Principal Supervisor	Brindisi Marie-Claude - Post-doctorate - CHU Bocage (Dijon, France) - Completed Student Degree Start Date: 2004/12 Student Degree Received Date: 2007/4 Project Description: Effets de l'acarbose et du répaglinide sur le stress oxydatif... Present Position: Endocrinologist, Dijon (France)

Principal Supervisor	Geneviève Beauregard, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2003/1 Student Degree Received Date: 2005/1 Project Description: Étude de la régulation de l'expression des gènes par l'insuline et le glucose
Principal Supervisor	Demiana Ekladous, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2003/1 Student Degree Received Date: 2005/6 Project Description: Hepatic resistance to glucagon
Co-Supervisor	Amélie Pelletier, - Doctorate - Université de Montréal - Completed Student Degree Start Date: 2000/6 Student Degree Received Date: 2006/6 Project Description: Regulation of glucose uptake in cardiomyocytes Present Position: Research Coordinator
Principal Supervisor	Sandra Bérubé, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2000/6 Student Degree Received Date: 2003/7 Project Description: Insulin sensitivity in a healthy population Present Position: private sector
Principal Supervisor	Yamina Boukhors, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 1998/9 Student Degree Received Date: 2003/8 Project Description: Use of information technology for management of ITT in type 1 diabetes Present Position: other

International Collaboration Activities

2008-01-01 - Member	United Kingdom Activity Description: The Acarbose Cardiovascular Evaluation (ACE) Trial
---------------------	--

Contributions

Presentations

2013-09-28	"Prevention of diabetes: Are we there yet?", At the Heart of Diabetes. An Essential Primer for Cardiovascular Renal and Metabolic Risk Reduction in Diabetes., Canada, Ontario, Toronto Main Audience: Researcher Invited?: Yes
2013-09-25	Vincent Poitout, "La glucotoxicité et la lipotoxicité dans le développement du diabète de type 2 et des complications vasculaires : approches fondamentales et cliniques.", Séminaire de la direction scientifique, Département de médecine, CHUM, Canada, Quebec, Montreal Main Audience: Researcher Invited?: Yes

2013-04-19	"Lignes directrices de pratique clinique pour la prévention et le traitement du diabète 2013", Endocrine Grand Round, Division of Endocrinology, CHUM, Canada, Quebec, Montreal Main Audience: Researcher Invited?: Yes
2013-03-29	"Pré-diabète: faut-il le traiter ?", Congrès de la Société Francophone du diabète 2013, France, Montpellier Main Audience: Researcher Invited?: Yes
2013-02-05	"Treatment of diabetes mellitus and the vascular complications.", SANOFI Guest speaker, Canada, Quebec, Laval Main Audience: Researcher Invited?: Yes
2012-11-29	"Treating postprandial hyperglycaemia for the prevention of cardiovascular disease.", National Atherosclerosis and Cardiometabolic Forum, Canada, Ontario, Toronto Main Audience: Researcher Invited?: Yes
2012-11-13	"Les complications vasculaires du diabète de type 2: peut-on les freiner?", Eli Lilly Guest Speaker, Canada, Quebec, Montreal Main Audience: Researcher Invited?: Yes
2012-10-26	"Mieux traiter les troubles métaboliques des patients VIH en 2012.", Dépistage et gestion du diabète chez le patient VIH, Canada, Quebec, Montréal Main Audience: Researcher Invited?: Yes
2012-07-13	"Treating postprandial plasma glucose for the prevention of diabetes and CVD: the STOP-NIDDM Trial.", Bayer Scientific Meeting., China, Beijing Main Audience: Researcher Funding Sources: Bayer HealthCare AG - 0
2012-04-14	"La glycémie postprandiale et le risque cardiovasculaire.", Bayer Scientific Symposium, Tunisia, Djerba Main Audience: Researcher Funding Sources: Bayer AG - 0
2012-04-13	"Le rôle des incrétines dans le diabète de type 2.", 21e Congrès National d'Endocrinologie de la Société Tunisienne d'Endocrinologie, Diabète et Maladies Métaboliques, Tunisia, Tunis Main Audience: Researcher Funding Sources: Bayer AG - 0
2012-04-13	"Le traitement de l'hyperglycémie postprandiale pour la prévention du diabète et des complications cardiovasculaires.", 21e Congrès National d'Endocrinologie de la Société Tunisienne d'Endocrinologie, Diabète et Maladies Métaboliques, Tunisia, Tunis Main Audience: Researcher Funding Sources: Bayer AG - 0

2012-04-12	"La glycémie et le risque cardiovasculaire.", Bayer Guest Speaker, Tunisia, Tunis Main Audience: Researcher Funding Sources: Bayer AG - 0
2012-04-11	"La glycémie postprandiale et le risque cardiovasculaire.", Bayer Guest Speaker, Tunisia, Sfax Main Audience: Researcher Funding Sources: Bayer AG - 0
2011-12-05	"Disposition index and the conversion of IGT to diabetes mellitus: The STOP-NIDDM Trial.", International Diabetes Federation 2011 (IDF 2011). Session: Insulin resistance in young and old., United Arab Emirates, Dubai Main Audience: Researcher
2011-08-26	"Le rôle de la microflore intestinale dans le développement de l'obésité.", Guest Speaker Sanofi, Scientific Grand Round, Division of Endocrinology, CHUM, Canada, Quebec, Montréal Main Audience: Researcher
2011-07-19	"Glucose control and cardiovascular disease.", ACE Regional Investigator Meeting, Speaker Tour, China, Guangzhou Main Audience: Researcher
2011-07-17	"Glucose control and cardiovascular disease.", ACE Regional Investigator Meeting, Speaker Tour., China, Hangzhou Main Audience: Researcher
2011-06-02	"Traiter l'hyperglycémie postprandiale pour la prévention du diabète et des complications vasculaires.", Sanofi Aventis Guest speaker, Division of Endocrinology, Montreal Jewish Hospital., Canada, Quebec, Montreal Main Audience: Researcher
2011-05-05	"Traiter l'hyperglycémie postprandiale pour diminuer le risque de diabète et de ses complications vasculaires.", Bayer Workshop., France, Nice Main Audience: Researcher
2011-03-05	"How to achieve safe and long-term glycaemic control with cardiovascular benefits.", Bayer Schering Pharma, 2nd Cardiovascular Risk Management Symposium. The Challenge of Cardiovascular Disease Prevention., France, Nice Main Audience: Researcher
2010-05-30	"CSN Debate: Hemoglobin A1C should be normalized with intensive insulin therapy to prevent macro- and microvascular disease in type 2 diabetes. Affirmative: Jean-Louis Chiasson, Negative: Richard Gilbert", Canadian Society of Nephrology Annual General Meeting 2010., Canada, Quebec, Montreal Main Audience: Researcher
2010-05-15	"L'hyperglycémie post-prandiale, son rôle délétère et sa prise en charge.", Congrès annuel de la Société Algérienne de Diabétologie., Algeria, Alger Main Audience: Researcher
2010-05-15	"La prévention du diabète de type 2.", Congrès annuel de la Société Algérienne de Diabétologie., Algeria, Alger Main Audience: Researcher

2010-05-08	"Evidence for CV benefits with acarbose intervention.", Bayer Schering Pharma Asia-Pacific Cardiovascular Risk Management Expert Workshop., Taiwan, Province of China, Taipei Main Audience: Researcher
2010-05-07	"Effects of oral diabetic drugs on CVD.", Bayer Schering Pharma Asia-Pacific ACE Speaker. Training Workshop., Taiwan, Province of China, Taipei Main Audience: Researcher
2010-04-22	"Atteindre les cibles en diabète: Nouvelles options pour l'insulinothérapie.", Sanofi Aventis Guest Speaker. Division of Endocrinology, Montreal Jewish Hospital., Canada, Quebec, Montreal Main Audience: Researcher
2009-10-20	"Guest speaker and Chairman: Intervention multifactorielle dans le traitement du diabète de type 2.", Optimizing long-term glycemic control in type 2 diabetes: Overcoming a progressive pathophysiology with incretin therapy (WorldWIDE), Symposium during the 20th IDF World Diabetes Congress., Canada, Quebec, Montreal Main Audience: Researcher
2009-10-20	"Debate on Primary prevention programmes for diabetes: lifestyle versus drugs - Drugs.", 20th IDF World Diabetes Congress., Canada, Quebec, Montreal Main Audience: Researcher
2009-10-18	"Guest speaker and Chairman. Glucose lowering interventions in diabetes and CVD - lessons from outcome studies.", Bayer Healthcare Satellite Symposium, 20th IDF World Diabetes Congress, Canada, Quebec, Montreal Main Audience: Researcher
2009-10-18	"Traiter l'hyperglycémie postprandiale pour diminuer le risque de diabète et de ses complications vasculaires.", Bayer Healthcare Meet the Expert Session, 20th IDF World Diabetes Congress., Canada, Quebec, Montreal Main Audience: Researcher
2009-10-08	"Postprandial peak reduction and its implication in the prevention of CV risk and diabetes.", Congress of Obesity, Metabolic Syndrome and Prediabetes., Venezuela, Bolivarian Republic of, Caracas Main Audience: Researcher
2009-05-29	"La prévention du diabète de type 2 et de ses complications.", Guest speaker Eli Lilly, Division of Endocrinology., Canada, New Brunswick, Moncton Main Audience: Researcher
2009-04-24	"Stratégies de sensibilisation à l'insuline et d'apport d'insuline dans le traitement du diabète de type 2. Quand et pourquoi ?", Diabetes Forum., Canada, Quebec, Montreal Main Audience: Researcher
2009-02-28	"Postprandial plasma glucose as a risk factor for cardiovascular disease.", Endocrine Grand Round, Division of Endocrinology, University of Toronto., Canada, Ontario, Toronto Main Audience: Researcher
2009-02-27	"The benefits of early insulin as opposed to oral hypoglycemic agents in type 2 diabetes.", Canadian Society of Endocrinology and Metabolism., Canada, Ontario, Toronto Main Audience: Researcher

2009-02-26	"L'insulinothérapie : Initiation pratique et nouvelles insulines.", SSVQ Symposium (Société des sciences vasculaires du Québec) - Le diabète: démystifier l'insulinothérapie et les nouveaux hypoglycémifiants oraux., Canada, Quebec, Montreal Main Audience: Researcher
------------	--

Interviews and Media Relations

Broadcast Interviews

2013-01-15 - 2013-01-15	Type 2 diabetes "Les docteurs" - Radio-Canada
----------------------------	--

Publications

PubMed Articles

	Chiasson JL, "Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.", Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 12 Suppl 1 PubMed ID: 16627376
2013-06-04	Althouse AD , Abbott JD , Sutton-Tyrrell K , Forker AD , Lombardero MS , Buitrón LV , Pena-Sing I , Tardif JC , Mori Brooks M , , "Favorable Effects of Insulin Sensitizers Pertinent to Peripheral Arterial Disease in Type 2 Diabetes: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.", Diabetes care PubMed ID: 23735723
2013-05-08	Leong A , Dasgupta K , Chiasson JL , Rahme E, "Estimating the Population Prevalence of Diagnosed and Undiagnosed Diabetes.", Diabetes care PubMed ID: 23656982
2013-04-30	Tamis-Holland JE , Lu J , Korytkowski M , Magee M , Rogers WJ , Lopes N , Mighton L , Jacobs AK , , "Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revasc", Journal of the American College of Cardiology, 61(17) PubMed ID: 23500245
2013-04-16	Farkouh ME , Boden WE , Bittner V , Muratov V , Hartigan P , Ogdie M , Bertolet M , Mathewkutty S , Teo K , Maron DJ , Sethi SS , Domanski M , Frye RL , Fuster V, "Risk factor control for coronary artery disease secondary prevention in large randomized trials.", Journal of the American College of Cardiology, 61(15) PubMed ID: 23500281
2013-03-07	Ismail-Beigi F , Lombardero MS , Escobedo J , Genuth S , Green J , Massaro E , Mooradian AD , Ovalle F , Whitehouse F , Zonszein J , , "Determinants of successful glycemic control among participants in the BARI 2D Trial: A Post-hoc Analysis.", Journal of diabetes and its complications PubMed ID: 23478173

2013-01-01	Wolever, T.M.S., Gibbs, A.L., Chiasson, J.L., Connelly, P.W., Josse, R.G., Leiter, L.A., Maheux, P., Rabasa-Lhoret, R., Rodger, N.W., Ryan, E.A., "Altering source or amount of dietary carbohydrate has acute and chronic effects on postprandial glucose and triglycerides in type 2 diabetes: Canadian trial of Carbohydrates in Diabetes (CCD).", <i>Nutr. Metab. Cardiovasc. Dis.</i> , 23 PubMed ID: 22397878
2012-12-20	Farkouh ME , Domanski M , Sleeper LA , Siami FS , Dangas G , Mack M , Yang M , Cohen DJ , Rosenberg Y , Solomon SD , Desai AS , Gersh BJ , Magnuson EA , Lansky A , Boineau R , Weinberger J , Ramanathan K , Sousa JE , Rankin J , Bhargava B , Buse J , Hueb W , Smith CR , Muratov V , Bansilal S , King S , Bertrand M , Fuster V , , "Strategies for multivessel revascularization in patients with diabetes.", <i>The New England journal of medicine</i> , 367(25) PubMed ID: 23121323
2012-12-01	Bergenstal RM , Forti A , Chiasson JL , Woloschak M , Boldrin M , Balena R , "Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial).", <i>Diabetes therapy : research, treatment and education of diabetes and related disorders</i> , 3(1) PubMed ID: 23138449
2012-07-01	Hanefeld M , Pistrosch F , Koehler C , Chiasson JL , "Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial.", <i>Journal of hypertension</i> , 30(7) PubMed ID: 22573126
2012-03-23	Henderson M , Baillargeon JP , Rabasa-Lhoret R , Chiasson JL , Hanley J , Lambert M , "Estimating insulin secretion in youth using simple indices derived from the oral glucose tolerance test.", <i>Diabetes & metabolism</i> PubMed ID: 22445514
2012-03-05	Wolever TM , Gibbs AL , Chiasson JL , Connelly PW , Josse RG , Leiter LA , Maheux P , Rabasa-Lhoret R , Rodger NW , Ryan EA , "Altering source or amount of dietary carbohydrate has acute and chronic effects on postprandial glucose and triglycerides in type 2 diabetes: Canadian trial of Carbohydrates in Diabetes (CCD).", <i>Nutrition, metabolism, and cardiovascular diseases : NMCD</i> PubMed ID: 22397878
2011-12-01	Broderick TL , El Midaoui A , Chiasson JL , Wang D , Jankowski M , Gutkowska J , "The effects of exercise training on #-butyrobetaine hydroxylase and novel organic cation transporter-2 gene expression in the rat.", <i>Applied physiology, nutrition, and metabolism = Physiologie appliquée, nutrition et métabolisme</i> , 36(6) PubMed ID: 22014179
2011-06-01	"Incidence of diabetes following ramipril or rosiglitazone withdrawal.", <i>Diabetes care</i> , 34(6) PubMed ID: 21515846
2011-03-01	Gerstein HC , Mohan V , Avezum A , Bergenstal RM , Chiasson JL , Garrido M , MacKinnon I , Rao PV , Zinman B , Jung H , Joldersma L , Bosch J , Yusuf S , "Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.", <i>Diabetologia</i> , 54(3) PubMed ID: 21116607

2011-02-01	Singh PP , Abbott JD , Lombardero MS , Sutton-Tyrrell K , Woodhead G , Venkitachalam L , Tsapatsaris NP , Piemonte TC , Lago RM , Rutter MK , Nesto RW ,, "The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.", Diabetes care, 34(2) PubMed ID: 21270200
2011-02-01	Henderson M , Rabasa-Lhoret R , Bastard JP , Chiasson JL , Baillargeon JP , Hanley JA , Lambert M, "Measuring insulin sensitivity in youth: How do the different indices compare with the gold-standard method?", Diabetes & Metabolism, 37(1) PubMed ID: 21126900
2010-02-01	Tuomilehto J , Lindström J , Hellmich M , Lehmacher W , Westermeier T , Evers T , Brückner A , Peltonen M , Qiao Q , Chiasson JL, "Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.", Diabetes research and clinical practice, 87(2) PubMed ID: 20022651
2009-11-01	Chiasson JL, "Early insulin use in type 2 diabetes: what are the cons?", Diabetes care, 32 Suppl 2 PubMed ID: 19875563
2009-11-01	de Galan BE , Zoungas S , Chalmers J , Anderson C , Dufouil C , Pillai A , Cooper M , Grobbee DE , Hackett M , Hamet P , Heller SR , Lisheng L , Macmahon S , Mancía G , Neal B , Pan CY , Patel A , Poulter N , Travert F , Woodward M ,, "Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.", Diabetologia, 52(11) PubMed ID: 19688336
2009-11-01	Zoungas S , de Galan BE , Ninomiya T , Grobbee D , Hamet P , Heller S , MacMahon S , Marre M , Neal B , Patel A , Woodward M , Chalmers J , , Cass A , Glasziou P , Harrap S , Lisheng L , Mancía G , Pillai A , Poulter N , Perkovic V , Travert F, "Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.", Diabetes care, 32(11) PubMed ID: 19651921
2009-06-11	Frye RL , August P , Brooks MM , Hardison RM , Kelsey SF , MacGregor JM , Orchard TJ , Chaitman BR , Genuth SM , Goldberg SH , Hlatky MA , Jones TL , Molitch ME , Nesto RW , Sako EY , Sobel BE, "A randomized trial of therapies for type 2 diabetes and coronary artery disease.", The New England journal of medicine, 360(24) PubMed ID: 19502645
2009-03-01	Hammana I , Coderre L , Potvin S , Costa M , Berthiaume Y , Lavoie A , Chiasson JL , Levy E , Rabasa-Lhoret R, "Dichotomy between postprandial glucose and lipid profiles in adults with cystic fibrosis: a pilot study.", Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 8(2) PubMed ID: 19083274

2009-03-01	Pop-Busui R , Lu J , Lopes N , Jones TL ,, "Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.", Journal of the peripheral nervous system : JPNS, 14(1) PubMed ID: 19335534
2009-01-01	Hanefeld M , Karasik A , Koehler C , Westermeier T , Chiasson JL, "Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.", Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease, 6(1) PubMed ID: 19156626
2008-12-01	Sreenan S , Virkamäki A , Zhang K , Hansen JB ,, "Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.", International journal of clinical practice, 62(12) PubMed ID: 19166444
2008-12-01	Godbout A , Hammana I , Potvin S , Mainville D , Rakel A , Berthiaume Y , Chiasson JL , Coderre L , Rabasa-Lhoret R, "No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes.", Diabetes & metabolism, 34(6 Pt 1) PubMed ID: 18922724
2008-09-01	Wolever TM , Mehling C , Chiasson JL , Josse RG , Leiter LA , Maheux P , Rabasa-Lhoret R , Rodger NW , Ryan EA, "Low glycaemic index diet and disposition index in type 2 diabetes (the Canadian trial of carbohydrates in diabetes): a randomised controlled trial.", Diabetologia, 51(9) PubMed ID: 18648764
2008-09-01	"Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.", American heart journal, 156(3) PubMed ID: 18760137
2008-08-01	Ekladous D , Mehdi MZ , Costa M , Srivastava AK , Chiasson JL , Coderre L, "Tissue- and fibre-specific modifications of insulin-signalling molecules in cardiac and skeletal muscle of diabetic rats.", Clinical and experimental pharmacology & physiology, 35(8) PubMed ID: 18430054
2008-07-01	Cloutier G , Zimmer A , Yu FT , Chiasson JL, "Increased shear rate resistance and fastest kinetics of erythrocyte aggregation in diabetes measured with ultrasound.", Diabetes care, 31(7) PubMed ID: 18375419
2008-06-12	Patel A , MacMahon S , Chalmers J , Neal B , Billot L , Woodward M , Marre M , Cooper M , Glasziou P , Grobbee D , Hamet P , Harrap S , Heller S , Liu L , Mancia G , Mogensen CE , Pan C , Poulter N , Rodgers A , Williams B , Bompont S , de Galan BE , Joshi R , Travert F, "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.", The New England journal of medicine, 358(24) PubMed ID: 18539916

2008-05-01	Dagenais GR , Gerstein HC , Holman R , Budaj A , Escalante A , Hedner T , Keltai M , Lonn E , McFarlane S , McQueen M , Teo K , Sheridan P , Bosch J , Pogue J , Yusuf S, "Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.", <i>Diabetes care</i> , 31(5) PubMed ID: 18268075
2008-01-01	Wolever TM , Gibbs AL , Mehling C , Chiasson JL , Connelly PW , Josse RG , Leiter LA , Maheux P , Rabasa-Lhoret R , Rodger NW , Ryan EA, "The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycosylated hemoglobin but reduction in C-reactive protein.", <i>The American journal of clinical nutrition</i> , 87(1) PubMed ID: 18175744
2007-12-01	Chiasson JL, "Prevention of Type 2 diabetes: fact or fiction?", <i>Expert opinion on pharmacotherapy</i> , 8(18) PubMed ID: 18035959
2007-11-30	Costa M , Potvin S , Hammana I , Malet A , Berthiaume Y , Jeanneret A , Lavoie A , Lévesque R , Perrier J , Poisson D , Karelis AD , Chiasson JL , Rabasa-Lhoret R, "Increased glucose excursion in cystic fibrosis and its association with a worse clinical status.", <i>Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society</i> , 6(6) PubMed ID: 17409029
2007-10-01	Godbout A , Chiasson JL, "Who should benefit from the use of alpha-glucosidase inhibitors?", <i>Current diabetes reports</i> , 7(5) PubMed ID: 18173965
2007-09-08	Patel A , , MacMahon S , Chalmers J , Neal B , Woodward M , Billot L , Harrap S , Poulter N , Marre M , Cooper M , Glasziou P , Grobbee DE , Hamet P , Heller S , Liu LS , Mancia G , Mogensen CE , Pan CY , Rodgers A , Williams B, "Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.", <i>Lancet</i> , 370(9590) PubMed ID: 17765963
2007-09-01	Fontaine-Bisson B , Wolever TM , Chiasson JL , Rabasa-Lhoret R , Maheux P , Josse RG , Leiter LA , Rodger NW , Ryan EA , Connelly PW , Corey PN , El-Sohemy A, "Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and fasting HDL-cholesterol and apo A-I concentrations.", <i>The American journal of clinical nutrition</i> , 86(3) PubMed ID: 17823444
2007-06-01	Hammana I , Malet A , Costa M , Brochiero E , Berthiaume Y , Potvin S , Chiasson JL , Coderre L , Rabasa-Lhoret R, "Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis.", <i>Diabetes & metabolism</i> , 33(3) PubMed ID: 17418606

2007-06-01	Chui MH , Papanikolaou Y , Fontaine-Bisson B , Turcotte J , Wolever TM , El-Sohemy A , Chiasson JL , Rabasa-Lhoret R , Maheux P , Ryan E , Greenwood CE, "The TNF-alpha-238G > a single-nucleotide polymorphism protects against memory decline in older adults with type 2 diabetes.", Behavioral neuroscience, 121(3) PubMed ID: 17592954
2007-05-01	Fontaine-Bisson B , Wolever TM , Chiasson JL , Rabasa-Lhoret R , Maheux P , Josse RG , Leiter LA , Rodger NW , Ryan EA , El-Sohemy A, "Tumor necrosis factor alpha -238G>A genotype alters postprandial plasma levels of free fatty acids in obese individuals with type 2 diabetes mellitus.", Metabolism: clinical and experimental, 56(5) PubMed ID: 17445540
2007-04-01	Andrulionyte L , Kuulasmaa T , Chiasson JL , Laakso M , , "Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.", Diabetes, 56(4) PubMed ID: 17317762
2007-04-01	Meugnier E , Faraj M , Rome S , Beauregard G , Michaut A , Pelloux V , Chiasson JL , Laville M , Clement K , Vidal H , Rabasa-Lhoret R, "Acute hyperglycemia induces a global downregulation of gene expression in adipose tissue and skeletal muscle of healthy subjects.", Diabetes, 56(4) PubMed ID: 17303805
2007-02-01	Pelletier A , Tardif A , Gingras MH , Chiasson JL , Coderre L, "Chronic exposure to ketone bodies impairs glucose uptake in adult cardiomyocytes in response to insulin but not vanadate: the role of PI3-K.", Molecular and cellular biochemistry, 296(1-2) PubMed ID: 16960657
2007-01-01	Brindisi MC , Hahn J , Chiasson JL , Rabasa-Lhoret R, "Under-utilization of capillary glucose monitoring by type 2 diabetic patients.", Diabetes research and clinical practice, 75(1) PubMed ID: 16814897
2006-10-12	Bosch J , Yusuf S , Gerstein HC , Pogue J , Sheridan P , Dagenais G , Diaz R , Avezum A , Lanas F , Probstfield J , Fodor G , Holman RR, "Effect of ramipril on the incidence of diabetes.", The New England journal of medicine, 355(15) PubMed ID: 16980380
2006-09-23	Gerstein HC , Yusuf S , Bosch J , Pogue J , Sheridan P , Dinccag N , Hanefeld M , Hoogwerf B , Laakso M , Mohan V , Shaw J , Zinman B , Holman RR, "Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.", Lancet, 368(9541) PubMed ID: 16997664
2006-08-01	Andrulionyte L , Laukkanen O , Chiasson JL , Laakso M , , "Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial.", Journal of molecular medicine (Berlin, Germany), 84(8) PubMed ID: 16838170

2006-07-01	Andrulionyte L , Peltola P , Chiasson JL , Laakso M ,, "Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.", <i>Diabetes</i> , 55(7) PubMed ID: 16804087
2006-06-19	Sobel BE ,, "Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial: Synergies and opportunities.", <i>The American journal of cardiology</i> , 97(12A) PubMed ID: 16813738
2006-06-19	Albu J , Gottlieb SH , August P , Nesto RW , Orchard TJ ,, "Modifications of coronary risk factors.", <i>The American journal of cardiology</i> , 97(12A) PubMed ID: 16813737
2006-06-19	Barsness GW , Gersh BJ , Brooks MM , Frye RL ,, "Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.", <i>The American journal of cardiology</i> , 97(12A) PubMed ID: 16813736
2006-06-19	Steiner G ,, "Statement of the problem.", <i>The American journal of cardiology</i> , 97(12A) PubMed ID: 16813733
2006-06-19	Magee MF , Isley WL ,, "Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.", <i>The American journal of cardiology</i> , 97(12A) PubMed ID: 16813735
2006-06-19	Brooks MM , Frye RL , Genuth S , Detre KM , Nesto R , Sobel BE , Kelsey SF , Orchard TJ ,, "Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.", <i>The American journal of cardiology</i> , 97(12A) PubMed ID: 16813734
2006-06-19	Hlatky MA , Melsop KA , Boothroyd DB ,, "Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease.", <i>The American journal of cardiology</i> , 97(12A) PubMed ID: 16813739
2006-04-13	Lonn E , Yusuf S , Arnold MJ , Sheridan P , Pogue J , Micks M , McQueen MJ , Probstfield J , Fodor G , Held C , Genest J ,, "Homocysteine lowering with folic acid and B vitamins in vascular disease.", <i>The New England journal of medicine</i> , 354(15) PubMed ID: 16531613
2006-04-01	Brindisi MC , Rabasa-Lhoret R , Chiasson JL, "Postprandial hyperglycaemia: to treat or not to treat?", <i>Diabetes & metabolism</i> , 32(2) PubMed ID: 16735958
2006-02-01	El Midaoui A , Chiasson JL , Tancrède G , Nadeau A, "Physical training reverses the increased activity of the hepatic ketone body synthesis pathway in chronically diabetic rats.", <i>American journal of physiology. Endocrinology and metabolism</i> , 290(2) PubMed ID: 16403781

2006-01-01	Lonn E , Held C , Arnold JM , Probstfield J , McQueen M , Micks M , Pogue J , Sheridan P , Bosch J , Genest J , Yusuf S ,, "Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.", The Canadian journal of cardiology, 22(1) PubMed ID: 16450017
------------	---

Journal Articles

2011/1 Published First Listed Author	Chiasson, J.L. and Bernard, S., "Reducing cardiovascular risk factors in patients with pre-diabetes.", Diabetes Management, 1, 423-438
2008/ Published Co-Author	Ur, E., Chiasson, J.L., Ransom, T., Rowe, R., "Screening for type 1 and type 2 diabetes.", Can. J. Diabetes, 32(Suppl 1), S14-S16
2008/ Published Co-Author	Ur, E., Chiasson, J.L., Ransom, T., Rowe, R., "Prevention of diabetes.", Can. J. Diabetes, 32(Suppl 1), S17-S19
2006/ Published First Listed Author	Chiasson, J.L., "Pharmacological and surgical intervention for the prevention of diabetes.", Nestlé Nutrition Workshop Ser. Clin. Perform. Programme, 11, 31-42

Book Chapters

2012/ In Press First Listed Author	"Decreasing postprandial plasma glucose in subjects with IGT using an # (alpha)-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: The STOP-NIDDM Trial.", Prevention of type 2 diabetes; From Science to Therapies, LeRoith, D., Ed., Springer Science Authors: Chiasson, J.L., Laakso, M., and Hanefeld, M.:
2012/ In Press Last Author	"Prevention of type 2 diabetes (chapter 38).", Diabetes in America, NIH Authors: Knowler, B., Chiasson, J.L.

Clinical Care Guidelines

2012-04-03	"2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada" Description / Contribution Value: The purpose of this review was to determine that there was no salient information missing, no conflicting recommendations, and that the recommendations are generally applicable to clinical practice.
------------	---